• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LAIR1 通过核粘着斑激酶依赖性 cyclin D1 表达和免疫抑制性趋化因子/细胞因子驱动胶质瘤进展。

LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.

机构信息

Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, P.R. China.

Department of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Yantai, Shandong, 264003, P.R. China.

出版信息

Cell Death Dis. 2023 Oct 16;14(10):684. doi: 10.1038/s41419-023-06199-9.

DOI:10.1038/s41419-023-06199-9
PMID:37845206
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10579300/
Abstract

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR1), an immune receptor containing immunoreceptor tyrosine-based inhibiory motifs (ITIMs), has emerged as an attractive target for cancer therapy. However, the intrinsic function of LAIR1 in gliomas remains unclear. In this study, the poor prognosis of glioma patients and the malignant proliferation of glioma cells in vitro and in vivo were found to be closely correlated with LAIR1. LAIR1 facilitates focal adhesion kinase (FAK) nuclear localization, resulting in increased transcription of cyclin D1 and chemokines/cytokines (CCL5, TGFβ2, and IL33). LAIR1 specifically supports in the immunosuppressive glioma microenvironment via CCL5-mediated microglia/macrophage polarization. SHP2 (PTP domain mutant) or FAK (non-nuclear localizing mutant) significantly reversed the LAIR1-induced growth enhancement in glioma cells. In addition, LAIR1 (ITIMs mutant) and SHP2 mutants significantly reduced FAK nuclear localization, as well as CCL5 and cyclin D1 expression. Further experiments revealed that the ITIMs of LAIR1 recruited SH2-containing phosphatase 2 (SHP2), which then interacted with FAK and induced FAK nuclear localization. This study uncovered a critical role for intrinsic LAIR1 in facilitating glioma malignant progression and demonstrated a requirement for LAIR1 and SHP2 to enhance FAK nuclear localization.

摘要

白细胞相关免疫球蛋白样受体 1(LAIR1)是一种含有免疫受体酪氨酸抑制基序(ITIM)的免疫受体,已成为癌症治疗的一个有吸引力的靶点。然而,LAIR1 在神经胶质瘤中的内在功能仍不清楚。本研究发现,神经胶质瘤患者的预后不良以及神经胶质瘤细胞在体外和体内的恶性增殖与 LAIR1 密切相关。LAIR1 促进粘着斑激酶(FAK)核定位,导致细胞周期蛋白 D1 和趋化因子/细胞因子(CCL5、TGFβ2 和 IL33)转录增加。LAIR1 通过 CCL5 介导的小胶质细胞/巨噬细胞极化,特异性支持免疫抑制性神经胶质瘤微环境。SHP2(PTP 结构域突变体)或 FAK(非核定位突变体)显著逆转了 LAIR1 诱导的神经胶质瘤细胞生长增强。此外,LAIR1(ITIM 突变体)和 SHP2 突变体显著降低了 FAK 的核定位以及 CCL5 和细胞周期蛋白 D1 的表达。进一步的实验表明,LAIR1 的 ITIM 募集了含 SH2 结构域的磷酸酶 2(SHP2),然后与 FAK 相互作用并诱导 FAK 核定位。本研究揭示了内在的 LAIR1 在促进神经胶质瘤恶性进展中的关键作用,并证明了 LAIR1 和 SHP2 增强 FAK 核定位的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/036c64dbacf5/41419_2023_6199_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/11a210499e49/41419_2023_6199_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/104f08455db1/41419_2023_6199_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/8b18bf7c2c7b/41419_2023_6199_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/7b0149f3ff00/41419_2023_6199_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/749162f7ff80/41419_2023_6199_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/09d468ccf03a/41419_2023_6199_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/036c64dbacf5/41419_2023_6199_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/11a210499e49/41419_2023_6199_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/104f08455db1/41419_2023_6199_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/8b18bf7c2c7b/41419_2023_6199_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/7b0149f3ff00/41419_2023_6199_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/749162f7ff80/41419_2023_6199_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/09d468ccf03a/41419_2023_6199_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6bee/10579300/036c64dbacf5/41419_2023_6199_Fig7_HTML.jpg

相似文献

1
LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.LAIR1 通过核粘着斑激酶依赖性 cyclin D1 表达和免疫抑制性趋化因子/细胞因子驱动胶质瘤进展。
Cell Death Dis. 2023 Oct 16;14(10):684. doi: 10.1038/s41419-023-06199-9.
2
Nuclear Focal Adhesion Kinase Controls Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia Through GATA4-Mediated Cyclin D1 Transcription.核局灶黏附激酶通过 GATA4 介导线粒体 cyclin D1 转录控制血管平滑肌细胞增殖和新生内膜增生。
Circ Res. 2019 Jul 5;125(2):152-166. doi: 10.1161/CIRCRESAHA.118.314344. Epub 2019 May 17.
3
Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.黏着斑激酶(FAK)对细胞周期蛋白D1启动子的转录激活作用有助于细胞周期进程。
Mol Biol Cell. 2001 Dec;12(12):4066-77. doi: 10.1091/mbc.12.12.4066.
4
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.p27Kip1和细胞周期蛋白D1对于在体外培养以及在无胸腺裸鼠脑内体内增殖的胶质母细胞瘤细胞中粘着斑激酶对细胞周期进程的调节是必需的。
J Biol Chem. 2005 Feb 25;280(8):6802-15. doi: 10.1074/jbc.M409180200. Epub 2004 Nov 19.
5
SH2 domain-containing protein tyrosine phosphatase 2 and focal adhesion kinase protein interactions regulate pulmonary endothelium barrier function.含SH2结构域的蛋白酪氨酸磷酸酶2与粘着斑激酶的蛋白相互作用调节肺内皮屏障功能。
Am J Respir Cell Mol Biol. 2015 Jun;52(6):695-707. doi: 10.1165/rcmb.2013-0489OC.
6
FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation.FAK 在核内通过促进 Skp2 降解来增加 p27 和 p21 的表达,从而阻止 VSMC 增殖。
Cardiovasc Res. 2022 Mar 16;118(4):1150-1163. doi: 10.1093/cvr/cvab132.
7
SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability the PI3K/AKT/GSK3β signaling pathway.SHP2 通过调节细胞周期蛋白 D1 的稳定性来促进乳腺癌细胞的增殖,该过程涉及到 PI3K/AKT/GSK3β 信号通路。
Cancer Biol Med. 2020 Aug 15;17(3):707-725. doi: 10.20892/j.issn.2095-3941.2020.0056.
8
Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.Shp2通过控制粘着斑激酶/Src和mTOR信号通路对心肌细胞的生长起负向调节作用。
Circ Res. 2008 Oct 10;103(8):813-24. doi: 10.1161/CIRCRESAHA.108.179754. Epub 2008 Aug 28.
9
Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.SHP2和YAP1的核定位与非小细胞肺癌不良预后的关联。
Pathol Res Pract. 2019 Apr;215(4):801-806. doi: 10.1016/j.prp.2019.01.027. Epub 2019 Jan 18.
10
Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways.Src通过激活粘着斑激酶/细胞外信号调节激酶1/2和磷脂酰肌醇3-激酶途径介导催乳素依赖性的T47D和MCF7细胞增殖。
Mol Endocrinol. 2003 Nov;17(11):2268-82. doi: 10.1210/me.2002-0422. Epub 2003 Aug 7.

引用本文的文献

1
Blocking immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response.用抗体阻断或三功能嵌合抗原受体(CAR)T细胞阻断免疫检查点LAIR1可增强抗肿瘤反应。
J Clin Invest. 2025 Jul 1;135(16). doi: 10.1172/JCI184043.
2
The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion.LAIR1作为抗肿瘤免疫细胞反应以及肿瘤细胞生长与增殖的调节性受体的作用。
Biomolecules. 2025 Jun 13;15(6):866. doi: 10.3390/biom15060866.
3
Inhibitory pattern recognition receptors: lessons from LAIR1.

本文引用的文献

1
A comprehensive review of SHP2 and its role in cancer.SHP2 及其在癌症中的作用的全面综述。
Cell Oncol (Dordr). 2022 Oct;45(5):729-753. doi: 10.1007/s13402-022-00698-1. Epub 2022 Sep 6.
2
Targeting NQO1/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth.通过白花丹醌靶向 NQO1/GPX4 介导的铁死亡抑制体外和体内神经胶质瘤生长。
Br J Cancer. 2022 Jul;127(2):364-376. doi: 10.1038/s41416-022-01800-y. Epub 2022 Apr 8.
3
Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication.
抑制性模式识别受体:来自LAIR1的经验教训。
Nat Rev Immunol. 2025 May 27. doi: 10.1038/s41577-025-01181-2.
4
Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy.通过共抑制受体解析T细胞耗竭及其在癌症免疫治疗中的变革性作用。
Clin Transl Med. 2025 May;15(5):e70345. doi: 10.1002/ctm2.70345.
5
ARHGDIB as a prognostic biomarker and modulator of the immunosuppressive microenvironment in glioma.ARHGDIB作为胶质瘤免疫抑制微环境的预后生物标志物和调节因子。
Cancer Immunol Immunother. 2025 May 15;74(7):204. doi: 10.1007/s00262-025-04063-7.
6
The integrin adhesome and control of anti-tumour immunity.整合素黏附体与抗肿瘤免疫的调控
Biochem Soc Trans. 2024 Dec 19;52(6):2455-2468. doi: 10.1042/BST20240386.
7
The mechanism of cytokine regulation of cancer occurrence and development in the tumor microenvironment and its application in cancer treatment: a narrative review.细胞因子在肿瘤微环境中对癌症发生发展的调控机制及其在癌症治疗中的应用:一篇叙述性综述
Transl Cancer Res. 2024 Oct 31;13(10):5649-5663. doi: 10.21037/tcr-24-679. Epub 2024 Oct 18.
8
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?调节胶质母细胞瘤浸润性髓样细胞上的免疫检查点是否是一种可行的治疗策略?
Neuro Oncol. 2025 Jan 12;27(1):33-49. doi: 10.1093/neuonc/noae193.
9
Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression.肿瘤微环境中粘着斑激酶介导的肿瘤与免疫细胞间相互作用:对癌症相关治疗及肿瘤进展的意义
Clin Transl Oncol. 2025 Apr;27(4):1398-1405. doi: 10.1007/s12094-024-03723-x. Epub 2024 Sep 13.
10
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review.调节性 T 细胞在肿瘤微环境中的潜在抗肿瘤作用:综述。
J Transl Med. 2024 Mar 20;22(1):293. doi: 10.1186/s12967-024-05104-y.
通过阻断 LAIR-1 和 TGF-β 信号重塑肿瘤微环境可实现 PD-L1 介导的肿瘤清除。
J Clin Invest. 2022 Apr 15;132(8). doi: 10.1172/JCI155148.
4
New Insights on the Nuclear Functions and Targeting of FAK in Cancer.FAK 在癌症中的核功能与靶向新见解。
Int J Mol Sci. 2022 Feb 11;23(4):1998. doi: 10.3390/ijms23041998.
5
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
6
Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.鉴定弥漫性神经胶质瘤 mRNA 疫苗开发中的三个肿瘤抗原和免疫亚型。
Theranostics. 2021 Oct 3;11(20):9775-9790. doi: 10.7150/thno.61677. eCollection 2021.
7
Tumour burden and efficacy of immune-checkpoint inhibitors.肿瘤负担与免疫检查点抑制剂的疗效。
Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12.
8
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.双 checkpoint 阻断 CD47 和 PD-L1 利用亲和力优化的双特异性抗体最大限度地提高抗肿瘤免疫。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003464.
9
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.肿瘤细胞 IDO 增强免疫抑制作用并降低胶质母细胞瘤患者的存活率,与色氨酸代谢无关。
Clin Cancer Res. 2021 Dec 1;27(23):6514-6528. doi: 10.1158/1078-0432.CCR-21-1392. Epub 2021 Sep 3.
10
Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1.间质肺巨噬细胞和单核细胞的动态平衡功能受胶原结构域结合受体 LAIR1 的调节。
Immunity. 2021 Jul 13;54(7):1511-1526.e8. doi: 10.1016/j.immuni.2021.06.012.